Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: Structural features and pharmacological potential

Cellular and Molecular Life Sciences

Volumn 71, Issue 16, 2014, Pages 3173-3185

  Cozza, Giorgio ^a   Girardi, Cristina ^a   Ranchio, Alessandro ^b   Lolli, Graziano ^b   Sarno, Stefania ^a   Orzeszko, Andrzej ^c   Kazimierczuk, Zygmunt ^c   Battistutta, Roberto ^b   Ruzzene, Maria ^a   Pinna, Lorenzo A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^c WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

Cancer; CK2; Dual kinase inhibitors; Pim 1; Protein phosphorylation; Signal transduction

Indexed keywords

1 (BETA DEXTRO 2' DEOXYRIBOFURANOSYL) 4,5,6,7 TETRABROMO 1H BENZIMIDAZOLE; 1 (BETA DEXTRO 2' DEOXYRIBOFURANOSYL) 4,5,6,7 TETRACHLORO 1H BENZIMIDAZOLE; 1 (BETA DEXTRO 2' DEOXYRIBOFURANOSYL) 4,5,6,7 TETRAIODO 1H BENZIMIDAZOLE; 1 (BETA DEXTRO 2' DEOXYRIBOFURANOSYL) 4,7 DIBROMO 5,6 DICHLORO 1H BENZIMIDAZOLE; 1 (BETA DEXTRO 2' DEOXYRIBOFURANOSYL) 4,7 DIIODO 5,6 DICHLORO 1H BENZIMIDAZOLE; 1 (BETA DEXTRO 2' DEOXYRIBOFURANOSYL) 5,6, DICHLORO 1H BENZIMIDAZOLE; 1 (BETA DEXTRO 2' RIBOFURANOSYL) 4,5,6,7 TETRABROMO 1H BENZIMIDAZOLE; 4,5,6,7 TETRABROMO 1H BENZIMIDAZOLE; 5,6 DICHLORO 1 (BETA DEXTRO RIBOFURANOSYL)BENZIMIDAZOLE; 5,6 DICHLORO 1 (BETA RIBOFURANOSYL)BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; CASEIN KINASE II; CX 4945; ENZYME INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN KINASE PIM 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL MEMBRANE PERMEABILITY; CHEMOSENSITIVITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG STRUCTURE; EMBRYO; FEMALE; HUMAN; HUMAN CELL; NEWBORN;

BENZIMIDAZOLES; CASEIN KINASE II; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; HALOGENATION; HUMANS; KINETICS; MODELS, MOLECULAR; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-PIM-1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84905119768     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-013-1552-5     Document Type: Article

References (45)

1. Li R, Stafford JA (2009) Kinase inhibitoR drugs. Wiley, New York
2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
3. Cohen P, Alessi DR (2013) Kinase drug discovery - what's next in the field? ACS Chem Biol 8:96-104
4. Morphy R (2010) Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 53:1413-1437
5. Pinna LA (2012) Protein kinase CK2. Wiley, New York
6. Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J (2010) PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 95:1004-1015
7. Pagano MA, Bain J, Kazimierczuk Z, Sarno S, Ruzzene M, Di Maira G, Elliott M, Orzeszko A, Cozza G, Meggio F, Pinna LA (2008) The selectivity of inhibitors of protein kinase CK2: an update. Biochem J 415:353-365
8. Sarno S, Papinutto E, Franchin C, Bain J, Elliott M, Meggio F, Kazimierczuk Z, Orzeszko A, Zanotti G, Battistutta R, Pinna LA (2011) Atp site-directed inhibitors of protein kinase CK2: an update. Curr Top Med Chem 11:1340-1351
9. Lopez-Ramos M, Prudent R, Moucadel V, Sautel CF, Barette C, Lafanechere L, Mouawad L, Grierson D, Schmidt F, Florent JC, Filippakopoulos P, Bullock AN, Knapp S, Reiser JB, Cochet C (2010) New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights. FASEB J 24:3171-3185
10. Cozza G, Sarno S, Ruzzene M, Girardi C, Orzeszko A, Kazimierczuk Z, Zagotto G, Bonaiuto E, Di Paolo ML, Pinna LA (2013) Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases. Biochim Biophys Acta 1834:1402-1409
11. Kazimierczuk ZSR, Shugar D (1985) Stereospecific synthesis by the sodium salt glycosylation method of halogeno benzimidazole 2'-deoxyribose analogues of the inhibitor of hnRNA synthesis, 5,6-dichloro-1(β-D-ribofuranosyl) benzimidazole (DRB). Naturforsch 40C:715-720
12. Laudy AE, Moo-Puc R, Cedillo-Rivera R, Kazimierczuk Z, Orzeszko A (2012) Synthesis and antimicrobial activities of new polyhalogenated benzimidazoles. J Heter Chem 49:1059-1065
13. Budow S, Kozlowska M, Górska A, Kazimierczuk Z, Eickmeier H, La Colla P, Gosselin G, Seela F (2009) Substituted benzimidazoles: antiviral activity and synthesis of nucleosides. aRKIVOC 3:225-250
14. Battistutta R, Cozza G, Pierre F, Papinutto E, Lolli G, Sarno S, O'Brien SE, Siddiqui-Jain A, Haddach M, Anderes K, Ryckman DM, Meggio F, Pinna LA (2011) Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Biochemistry 50:8478-8488
15. Kabsch W (2010) Xds. Acta Crystallogr D Biol Crystallogr 66:125-132
16. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67:235-242
17. Mccoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) Phaser crystallographic software. J Appl Crystallogr 40:658-674
18. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501
19. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66:213-221
20. Molecular Operating Environment (MOe 2009.10) CCG, Inc, 1255 University St., Suite 1600, Montreal, Quebec, Canada, H3B 3X3
21. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727-748
22. Sarno S, Mazzorana M, Traynor R, Ruzzene M, Cozza G, Pagano MA, Meggio F, Zagotto G, Battistutta R, Pinna LA (2012) Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1a. Cell Mol Life Sci 69:449-460
23. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297-315
24. Graczyk PP (2007) Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. J Med Chem 50:5773-5779
25. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, Pinna LA, Ruzzene M (2005) Protein kinase CK2 phosphorylates and upregulates akt/PKB. Cell Death Differ 12:668-677
26. Di Maira G, Brustolon F, Bertacchini J, Tosoni K, Marmiroli S, Pinna LA, Ruzzene M (2007) Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene 26:6915-6926
27. Ruzzene M, Penzo D, Pinna LA (2002) Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 364:41-47
28. Zandomeni R, Zandomeni MC, Shugar D, Weinmann R (1986) Casein kinase type II is involved in the inhibition by 5,6-dichloro1-beta-D- ribofuranosylbenzimidazole of specific RNa polymerase II transcription. J Biol Chem 261:3414-3419
29. Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella Deana A, Shugar D, Pinna LA (2001) Selectivity of 4,5,6,7-tetra-bromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett 496:44-48
30. Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z, Pinna LA (2004) 2-Dimethylamino-4,5,6,7-tetrabromo-1h-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun 321:1040-1044
31. Meggio F, Shugar D, Pinna LA (1990) Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1. Eur J Biochem 187:89-94
32. Szyszka R, Grankowski N, Felczak K, Shugar D (1995) Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccharomyces cerevisiae and other sources. Biochem Biophys Res Commun 208:418-424
33. Raaf J, Brunstein E, Issinger OG, Niefind K (2008) The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules. Chem Biol 15:111-117
34. Pierre F, Regan CF, Chevrel MC, Siddiqui-Jain A, Macalino D, Streiner N, Drygin D, Haddach M, O'Brien SE, Rice WG, Ryckman DM (2012) Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells. Bioorg Med Chem Lett 22:3327-3331
35. St-Denis NA, Litchfield DW (2009) Protein kinase CK2 in health and disease: from birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell Mol Life Sci 66:1817-1829
36. Nawijn MC, Alendar A, Berns A (2011) For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 11:23-34
37. Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, van Waes C, Ahmed K (2010) Emergence of protein kinase CK2 as a key target in cancer therapy. BioFactors 36:187-195
38. Cozza G, Mazzorana M, Papinutto E, Bain J, Elliott M, Di Maira G, Gianoncelli A, Pagano MA, Sarno S, Ruzzene M, Battistutta R, Meggio F, Moro S, Zagotto G, Pinna LA (2009) Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem J 421:387-395
39. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD (2009) Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 52:74-86
40. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C, Proffitt C, Schwaebe MK, Ryckman DM, Rice WG, Anderes K (2010) CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70:10288-10298
41. Zanin S, Borgo C, Girardi C, O'Brien SE, Miyata Y, Pinna LA, Donella-Deana A, Ruzzene M (2012) Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells. PLoS ONe 7:e49193
42. Isaac M, Siu A, Jongstra J (2011) The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms. Drug Resist Updat 14:203-211
43. Glavy JS, Horwitz SB, Orr GA (1997) Identification of the in vivo phosphorylation sites for acidic-directed kinases in murine mdr1b P-glycoprotein. J Biol Chem 272:5909-5914
44. Stolarczyk EI, Reiling CJ, Pickin KA, Coppage R, Knecht MR, Paumi CM (2012) Casein kinase 2alpha regulates multidrug resistance-associated protein 1 function via phosphorylation of thr249. Mol Pharmacol 82:488-499
45. Ruzzene M, Di Maira G, Tosoni K, Pinna LA (2010) Assessment of CK2 constitutive activity in cancer cells. Methods Enzymol 484:495-514